Skip to main content
Top
Published in: Tumor Biology 9/2015

01-09-2015 | Research Article

miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma

Authors: Qing-Zhi Long, Yue-Feng Du, Xiao-Gang Liu, Xiang Li, Da-Lin He

Published in: Tumor Biology | Issue 9/2015

Login to get access

Abstract

Renal cell carcinoma (RCC) is one of most malignant neoplasms, exhibiting poor responsiveness to the conventional chemo-regime. Abnormal expression of P-glycoprotein (P-gp) has been implicated in the emergence of multiple-drug resistance (MDR) by reducing the accumulation of intracellular chemotherapy drugs. Wnt signaling plays critical roles in renal cancer and is triggered by binding of Wnt ligands to Frizzled (FZD) receptor proteins. miR-124 is a tumor suppressor associated with cancer relapse and MDR, whereas its role in P-gp-mediated MDR in refractory RCC is as yet unrevealed. Our study aimed to investigate the roles of miR-124 in chemo-resistant RCC cells and the potential targeted signaling paths in inducing P-gp expression. Doxorubicin (DOX)- and vinblastine (VBL)-resistant Caki-2 cells were developed by exposure of parental Caki-2 cells to the agents over a long period of time. In comparison with their parental cells, miR-124 was downregulated in Caki-2/DOX and Caki-2/VBL cells, accompanied by increased FZD5 and P-gp. IC50 values were reduced significantly after miR-124 mimics were introduced into Caki-2/DOX cells. In addition, miR-124 mimics significantly promoted apoptosis of Caki-2/DOX cells. miR-124 targeted to FZD5 and miR-124 mimics as well as FZD5 siRNA showed significant inhibitory effects on P-gp expression in Caki-2/DOX cells. Furthermore, Wnt-5a dose-dependently stimulated the presentation of p-PKCα/βII and p-CamKII via activating FZD5, which was reversed by FZD5 silencing. Moreover, FZD5/protein kinase C (PKC) signaling is responsible for the elevation of P-gp and cancer cell survival. In conclusion, restoring miR-124 may function as a promising strategy to overcome P-gp-mediated MDR by inhibiting FZD5/PKC signaling.
Literature
1.
go back to reference Walsh N, Larkin A, Kennedy S, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009;9:6.CrossRefPubMedPubMedCentral Walsh N, Larkin A, Kennedy S, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009;9:6.CrossRefPubMedPubMedCentral
2.
go back to reference Feng DD, Zhang H, Zhang P, et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2011;15:2164–75.CrossRefPubMedPubMedCentral Feng DD, Zhang H, Zhang P, et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med. 2011;15:2164–75.CrossRefPubMedPubMedCentral
3.
go back to reference Gowrishankar B, Ibragimova I, Zhou Y, et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther. 2014;15:329–41.CrossRefPubMed Gowrishankar B, Ibragimova I, Zhou Y, et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther. 2014;15:329–41.CrossRefPubMed
4.
go back to reference Gong J, Jaiswal R, Mathys JM, et al. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 2012;38:226–34.CrossRefPubMed Gong J, Jaiswal R, Mathys JM, et al. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev. 2012;38:226–34.CrossRefPubMed
5.
go back to reference Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20.CrossRefPubMedPubMedCentral Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20.CrossRefPubMedPubMedCentral
6.
go back to reference Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–8.CrossRefPubMedPubMedCentral Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76:582–8.CrossRefPubMedPubMedCentral
7.
go back to reference Chakravarthi BV, Pathi SS, Goswami MT, et al. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget. 2014;5:6654–69.CrossRefPubMedPubMedCentral Chakravarthi BV, Pathi SS, Goswami MT, et al. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget. 2014;5:6654–69.CrossRefPubMedPubMedCentral
8.
go back to reference Wan HY, Li QQ, Zhang Y, et al. MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett. 2014;355:148–58.CrossRefPubMed Wan HY, Li QQ, Zhang Y, et al. MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett. 2014;355:148–58.CrossRefPubMed
9.
go back to reference Jinushi T, Shibayama Y, Kinoshita I, et al. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 2014;34:1258–69. Jinushi T, Shibayama Y, Kinoshita I, et al. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 2014;34:1258–69.
10.
go back to reference Gebauer K, Peters I, Dubrowinskaja N, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013;108:131–8.CrossRefPubMedPubMedCentral Gebauer K, Peters I, Dubrowinskaja N, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013;108:131–8.CrossRefPubMedPubMedCentral
12.
go back to reference Hirata H, Ueno K, Nakajima K, et al. Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br J Cancer. 2013;108:2070–8.CrossRefPubMedPubMedCentral Hirata H, Ueno K, Nakajima K, et al. Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br J Cancer. 2013;108:2070–8.CrossRefPubMedPubMedCentral
13.
go back to reference Janssens N, Andries L, Janicot M, Perera T, Bakker A. Alteration of frizzled expression in renal cell carcinoma. Tumour Biol. 2004;25:161–71.CrossRefPubMed Janssens N, Andries L, Janicot M, Perera T, Bakker A. Alteration of frizzled expression in renal cell carcinoma. Tumour Biol. 2004;25:161–71.CrossRefPubMed
14.
go back to reference Kruck S, Eyrich C, Scharpf M, et al. Impact of an altered Wnt1/beta-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci. 2013;14:10944–57.CrossRefPubMedPubMedCentral Kruck S, Eyrich C, Scharpf M, et al. Impact of an altered Wnt1/beta-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma. Int J Mol Sci. 2013;14:10944–57.CrossRefPubMedPubMedCentral
15.
16.
go back to reference Pinzón-Daza ML, Salaroglio IC, Kopecka J, et al. The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood–brain barrier cells. J Cereb Blood Flow Metab. 2014;3:1544–52. Pinzón-Daza ML, Salaroglio IC, Kopecka J, et al. The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood–brain barrier cells. J Cereb Blood Flow Metab. 2014;3:1544–52.
17.
go back to reference Long Q-Z, Zhou M, Liu X-G, et al. Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells. Anticancer Drug. 2013;24:810–7.CrossRef Long Q-Z, Zhou M, Liu X-G, et al. Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells. Anticancer Drug. 2013;24:810–7.CrossRef
18.
go back to reference Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13:1859–76.CrossRefPubMed Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13:1859–76.CrossRefPubMed
19.
go back to reference Slaby O, Redova M, Poprach A, et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer. 2012;51:707–16.CrossRefPubMed Slaby O, Redova M, Poprach A, et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer. 2012;51:707–16.CrossRefPubMed
21.
go back to reference Asuthkar S, Stepanova V, Lebedeva T, et al. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell. 2013;24:2620–32.CrossRefPubMedPubMedCentral Asuthkar S, Stepanova V, Lebedeva T, et al. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell. 2013;24:2620–32.CrossRefPubMedPubMedCentral
22.
go back to reference Zang T, Zhuang L, Zhang Z, Xin D, Guo Y. Aberrant activity of Wnt/Frizzled signaling pathway in renal cancer cell lines. Chin Sci Bull. 2000;45:1703–7.CrossRef Zang T, Zhuang L, Zhang Z, Xin D, Guo Y. Aberrant activity of Wnt/Frizzled signaling pathway in renal cancer cell lines. Chin Sci Bull. 2000;45:1703–7.CrossRef
23.
go back to reference Rao Q, Liu XH, Zhou HB, et al. Expression analysis of Wnt-5a in renal epithelial neoplasms: distinguishing renal oncocytoma from a wide spectrum of renal cell carcinomas. Tumori. 2010;96:304–9.PubMed Rao Q, Liu XH, Zhou HB, et al. Expression analysis of Wnt-5a in renal epithelial neoplasms: distinguishing renal oncocytoma from a wide spectrum of renal cell carcinomas. Tumori. 2010;96:304–9.PubMed
24.
go back to reference Zhuang L, Zhang Z, Guo Y. Aberrant expression of growth factor Wnt-5A in six urinary malignant cell lines. Chin Med J (Engl). 1999;112:251–5. Zhuang L, Zhang Z, Guo Y. Aberrant expression of growth factor Wnt-5A in six urinary malignant cell lines. Chin Med J (Engl). 1999;112:251–5.
25.
go back to reference Flescher E, Rotem R. Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells. Cell Signal. 2002;14:37–43.CrossRefPubMed Flescher E, Rotem R. Protein kinase C epsilon mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells. Cell Signal. 2002;14:37–43.CrossRefPubMed
26.
go back to reference Gill PK, Gescher A, Gant TW. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and θ. Eur J Biochem. 2001;268:4151–7.CrossRefPubMed Gill PK, Gescher A, Gant TW. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and θ. Eur J Biochem. 2001;268:4151–7.CrossRefPubMed
Metadata
Title
miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma
Authors
Qing-Zhi Long
Yue-Feng Du
Xiao-Gang Liu
Xiang Li
Da-Lin He
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3369-3

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine